This dataset is used in the analyses reported in the review entitled "Interleukin (IL)-1 blocking agents for the treatment of COVID-19 A living systematic review" IL-1 blockers are beneficial in inflammation-associated pathologies, such as rheumatoid arthritis (Mertens 2009) and possibly also in the subgroup of patients with severe sepsis where the inflammasome pathway is involved (Shakoory 2016). Similar benefits were reported in children with secondary macrophage activation syndrome, including cases triggered by viral infections (Mehta 2020b). In this review we aimed to assess the effectiveness of IL-1 blocking agents compared to placebo, standard of care or no treatment on outcomes in patients with COVID-19. This review is part of a larger project: the COVID-NMA project. We set-up a platform (https://covid-nma.com) where all our results are made available and updated bi-weekly.